Hong Kong SFC Type 9 Responsible Officer (RO)

Master of Pharmacy (M.Pharm.)

China Pharmaceutical University

Former Roles:

Director of Pharmaceutical & Healthcare Business, Strategic Management Department, China Resources Group

General Manager of Investment & Development, China Resources Life Sciences Group

Production & Operations Director, GlaxoSmithKline (GSK)

• Ph.D., Zhejiang University; Postdoctoral Fellow, Baylor College of Medicine; Adjunct Professor, Zhejiang University School of Medicine

• Principal Investigator (PI) at an independent laboratory in the United States; Supervisor for doctoral students and postdoctoral fellows; Recipient of multiple research grants, including the R01 grant from the National Institutes of Health (NIH)

• A decade of experience in the pharmaceutical industry; previously worked at Lexicon Pharmaceuticals (USA), Hisun Pharma, and others; contributed to the market approval or clinical trial advancement of multiple products

• Former Partner at Yingke Capital; full-spectrum coverage of pharmaceuticals, medical devices, IVD, and CXO; invested in over 30 portfolio companies

Bachelor of Arts in Economics

University of Washington, U.S.A.

Ten years of experience in financial management and corporate operations.

Former Role:

Group Finance Department, Huawei Technologies Co., Ltd. — with deep expertise in financial coordination, internal control, and organizational management.

Current Role:

Member of the Management Decision Committee, with overall responsibility for corporate financial management, human resources & administration, and digital transformation initiatives. Committed to advancing the standardization of corporate governance systems and enhancing organizational effectiveness.

Bachelor's degree in Pharmacy from Shanghai Jiao Tong University and Master's degree in Finance from Durham University, UK, with a multidisciplinary background. Five years of investment experience, specializing in medical devices and new materials. Successfully exited 4 investments, including 2 IPO projects.